* Inozyme Pharma Inc reported a quarterly adjusted loss of 39 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -29 cents. The mean expectation of nine analysts for the quarter was for a loss of 44 cents per share. Wall Street expected results to range from -46 cents to -41 cents per share.
* Reported revenue was zero; analysts expected zero.
* Inozyme Pharma Inc's reported EPS for the quarter was a loss of 39 cents.
* The company reported a quarterly loss of $24.57 million.
* Inozyme Pharma Inc shares had fallen by 15.5% this quarter and gained 3.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 0.6% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Inozyme Pharma Inc is $15.00 This summary was machine generated from LSEG data November 6 at 04:57 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.44 -0.39 Beat
Jun. 30 2024 -0.39 -0.44 Missed
Mar. 31 2024 -0.36 -0.38 Missed
Dec. 31 2023 -0.32 -0.33 Missed
Comments